Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 77Pancreatic Neoplasms 56Stomach Neoplasms 52Rectal Neoplasms 43Esophageal Squamous Cell Carcinoma 38Esophageal Neoplasms 38Neoplasm Metastasis 25Colonic Neoplasms 23Neoplasms 15Cholangiocarcinoma 13Liver Neoplasms 10Gastrointestinal Neoplasms 10Breast Neoplasms 9Adenocarcinoma Of Esophagus 9Carcinoma, Hepatocellular 7Anus Neoplasms 7Lung Neoplasms 6Head and Neck Neoplasms 6Biliary Tract Neoplasms 6Ovarian Neoplasms 5Melanoma 5Adenocarcinoma 5Kidney Neoplasms 4Gastrointestinal Diseases 4Digestive System Neoplasms 4Carcinoma, Squamous Cell 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Sarcoma 3Lymphoma 3

Interventions

Gastrectomy 4apatinib 3Taxes 3S 1 (combination) 3Oxaliplatin 3Cisplatin 3sintilimab 2Paclitaxel 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Docetaxel 2Albumin-Bound Paclitaxel 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tipiracil 1taxane 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1andecaliximab 1XELOX 1Trifluridine 1Tegafur 1Tadalafil 1SHR-1701 1Resistance Training 1Radiotherapy 1Platinum 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastric Adenocarcinoma × Drug Therapy × Gastrointestinal × Clear all
NCT06798376 2025-01-29

Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer

Chinese PLA General Hospital

Recruiting
300 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT06667050 2024-10-31

CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

West China Hospital

Phase 2 Active not recruiting
58 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡